IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden · Delayed Price · Currency is SEK 1.268
+0.030 (2.42%)
At close: Jun 11, 2026
IRLAB Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 92.46 | 57.46 | 94.63 | 5.68 | 61.14 | 207.78 |
Other Revenue | -0 | - | - | - | - | - |
| 92.46 | 57.46 | 94.63 | 5.68 | 61.14 | 207.78 | |
Revenue Growth (YoY) | -6.59% | -39.28% | 1566.57% | -90.71% | -70.58% | 69160.67% |
Cost of Revenue | 96.91 | 99.38 | 136.29 | 128.41 | 125.91 | 81.74 |
Gross Profit | -4.45 | -41.91 | -41.66 | -122.73 | -64.77 | 126.05 |
Selling, General & Admin | 44.46 | 46.12 | 46.18 | 53.08 | 42.48 | 31.02 |
Other Operating Expenses | 0.89 | 1.05 | -19.46 | -0.04 | -0.03 | 38.97 |
Operating Expenses | 49.58 | 51.48 | 31.31 | 57.36 | 47.23 | 73.47 |
Operating Income | -54.03 | -93.4 | -72.97 | -180.09 | -112 | 52.58 |
Interest Expense | -14.36 | -17.99 | -10.48 | -0.2 | -0.3 | -0.37 |
Interest & Investment Income | 1.47 | 1.38 | 2.46 | 3.13 | - | 0 |
Currency Exchange Gain (Loss) | - | - | -2.14 | -0.68 | -1.11 | -0.43 |
Other Non Operating Income (Expenses) | - | -0 | - | 0 | - | - |
EBT Excluding Unusual Items | -66.92 | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 |
Pretax Income | -66.92 | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 |
Earnings From Continuing Operations | -66.92 | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 |
Net Income | -66.92 | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 |
Net Income to Common | -66.92 | -110.01 | -83.13 | -177.84 | -113.41 | 51.78 |
Shares Outstanding (Basic) | 75 | 67 | 52 | 52 | 52 | 52 |
Shares Outstanding (Diluted) | 75 | 67 | 52 | 52 | 52 | 52 |
Shares Change (YoY) | 43.64% | 29.17% | - | 0.07% | 0.16% | 8.54% |
EPS (Basic) | -0.90 | -1.64 | -1.60 | -3.43 | -2.19 | 1.00 |
EPS (Diluted) | -0.90 | -1.64 | -1.60 | -3.43 | -2.19 | 1.00 |
Free Cash Flow | -96.2 | -55.22 | -65.79 | -165.14 | -145.49 | 127.93 |
Free Cash Flow Per Share | -1.29 | -0.82 | -1.27 | -3.18 | -2.81 | 2.47 |
Gross Margin | -4.81% | -72.94% | -44.03% | - | -105.94% | 60.66% |
Operating Margin | -58.43% | -162.54% | -77.11% | -3171.72% | -183.20% | 25.30% |
Profit Margin | -72.37% | -191.45% | -87.85% | -3132.07% | -185.50% | 24.92% |
Free Cash Flow Margin | -104.04% | -96.10% | -69.52% | -2908.47% | -237.97% | 61.57% |
EBITDA | -49.79 | -89.08 | -72.08 | -179.17 | -111.27 | 53.07 |
EBITDA Margin | -53.85% | -155.02% | -76.17% | - | -182.00% | 25.54% |
D&A For EBITDA | 4.24 | 4.32 | 0.89 | 0.92 | 0.74 | 0.49 |
EBIT | -54.03 | -93.4 | -72.97 | -180.09 | -112 | 52.58 |
EBIT Margin | -58.43% | -162.54% | -77.11% | - | -183.20% | 25.30% |
Revenue as Reported | 95.24 | 62.8 | 114.08 | 5.72 | 61.28 | 207.91 |